Citadel Advisors’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.3M | Sell |
258,900
-319,800
| -55% | -$16.9M | ﹤0.01% | 2958 |
|
|
2025
Q4 | $30.3M | Sell |
578,700
-272,300
| -32% | -$16.3M | ﹤0.01% | 1890 |
|
|
2025
Q3 | $55.2M | Sell |
851,000
-124,800
| -13% | -$7.16M | 0.01% | 1282 |
|
|
2025
Q2 | $47.5M | Buy |
975,800
+550,300
| +129% | +$21.3M | 0.01% | 1272 |
|
|
2025
Q1 | $14.5M | Buy |
425,500
+133,200
| +46% | +$5.65M | ﹤0.01% | 2400 |
|
|
2024
Q4 | $11.5M | Buy |
292,300
+12,300
| +4% | +$581K | ﹤0.01% | 2804 |
|
|
2024
Q3 | $13.2M | Sell |
280,000
-91,000
| -25% | -$4.62M | ﹤0.01% | 2540 |
|
|
2024
Q2 | $20M | Sell |
371,000
-114,400
| -24% | -$6.62M | ﹤0.01% | 1998 |
|
|
2024
Q1 | $33.1M | Sell |
485,400
-214,300
| -31% | -$15.3M | 0.01% | 1567 |
|
|
2023
Q4 | $43.8M | Buy |
699,700
+309,200
| +79% | +$17.1M | 0.01% | 1287 |
|
|
2023
Q3 | $17.7M | Buy |
390,500
+50,500
| +15% | +$2.61M | ﹤0.01% | 1990 |
|
|
2023
Q2 | $19.1M | Buy |
340,000
+78,900
| +30% | +$4.48M | ﹤0.01% | 1941 |
|
|
2023
Q1 | $11.8M | Sell |
261,100
-151,600
| -37% | -$7.36M | ﹤0.01% | 2582 |
|
|
2022
Q4 | $16.8M | Sell |
412,700
-477,500
| -54% | -$25.3M | ﹤0.01% | 2156 |
|
|
2022
Q3 | $58.2M | Buy |
890,200
+11,900
| +1% | +$862K | 0.01% | 944 |
|
|
2022
Q2 | $53.4M | Buy |
878,300
+400,400
| +84% | +$23.5M | 0.01% | 966 |
|
|
2022
Q1 | $30M | Sell |
477,900
-22,400
| -4% | -$1.41M | 0.01% | 1552 |
|
|
2021
Q4 | $37.9M | Buy |
500,300
+133,200
| +36% | +$11.6M | 0.01% | 1401 |
|
|
2021
Q3 | $41.1M | Sell |
367,100
-24,000
| -6% | -$3.01M | 0.01% | 1282 |
|
|
2021
Q2 | $63.3M | Buy |
391,100
+41,400
| +12% | +$5.03M | 0.01% | 949 |
|
|
2021
Q1 | $42.6M | Buy |
349,700
+67,400
| +24% | +$10.2M | 0.01% | 1178 |
|
|
2020
Q4 | $43.2M | Buy |
282,300
+183,600
| +186% | +$21.7M | 0.01% | 1071 |
|
|
2020
Q3 | $8.26M | Sell |
98,700
-31,300
| -24% | -$2.78M | ﹤0.01% | 2523 |
|
|
2020
Q2 | $9.55M | Buy |
130,000
+46,900
| +56% | +$2.74M | ﹤0.01% | 2272 |
|
|
2020
Q1 | $3.52M | Sell |
83,100
-15,800
| -16% | -$816K | ﹤0.01% | 3213 |
|
|
2019
Q4 | $6.02M | Sell |
98,900
-8,400
| -8% | -$459K | ﹤0.01% | 2853 |
|
|
2019
Q3 | $4.4M | Buy |
107,300
+5,700
| +6% | +$272K | ﹤0.01% | 3286 |
|
|
2019
Q2 | $4.79M | Buy |
101,600
+23,000
| +29% | +$919K | ﹤0.01% | 3147 |
|
|
2019
Q1 | $2.81M | Buy |
78,600
+32,700
| +71% | +$1.13M | ﹤0.01% | 3871 |
|
|
2018
Q4 | $1.31M | Sell |
45,900
-8,100
| -15% | -$282K | ﹤0.01% | 4867 |
|
|
2018
Q3 | $2.4M | Sell |
54,000
-26,400
| -33% | -$1.38M | ﹤0.01% | 4102 |
|
|
2018
Q2 | $4.72M | Buy |
80,400
+58,300
| +264% | +$3.32M | ﹤0.01% | 2857 |
|
|
2018
Q1 | $1.01M | Buy |
+22,100
| New | +$912K | ﹤0.01% | 4786 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Citadel Advisors's CRSP Position: Q1 2026 in Review
Citadel Advisors increased its CRISPR Therapeutics (CRSP) stake by 93% in Q1 2026, buying an estimated $13.1M and bringing the position to 516,352 shares worth $24.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2082.
Citadel Advisors first reported a position in CRSP in Q4 2017 and has held it in 31 quarters since. The position peaked at $34.6M in Q4 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Citadel Advisors held 516,352 shares of CRISPR Therapeutics worth $24.6M as of Q1 2026.
- Citadel Advisors bought 248,667 CRISPR Therapeutics shares in Q1 2026, an estimated $13.1M.
- CRISPR Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2082 holding.
- Citadel Advisors first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 31 quarters since.
- Citadel Advisors's CRISPR Therapeutics position peaked at $34.6M in Q4 2024.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.